ライフサイエンスコーパス: engraftment

1 ost-HSCT (7/7), as early as day +14 (myeloid engraftment).

2 rapies are limited by poor cell survival and engraftment.

3 he irradiation dose that enhances donor cell engraftment.

4 und autoantibodies, and increased DSG3-CAART engraftment.

5 nd adhesion molecules orchestrating monocyte engraftment.

6 rapid and efficient donor hematopoietic cell engraftment.

7 m cardiac function despite a lack of durable engraftment.

8 is expressed after stem and progenitor cell engraftment.

9 oning, which associated with poor donor cell engraftment.

10 tion of bone marrow sprocs and their hepatic engraftment.

11 e marrow were similarly challenged following engraftment.

12 oxicity syndromes that occur upon CAR T-cell engraftment.

13 on and predict dopamine neuron content after engraftment.

14 rrhythmic effects of HC at various levels of engraftment.

15 olation and maintain CXCL10 production after engraftment.

16 esponse is required for effective donor cell engraftment.

17 long development time and low efficiency of engraftment.

18 -replete monocytes was sufficient to restore engraftment.

19 ution inflammatory syndrome (IRIS) following engraftment.

20 ssociated with any adverse events or delayed engraftment.

21 ue, which was also able to support human HSC engraftment.

22 ) after transient multi-organ failure or non-engraftment.

23 icient availability, and lack of appropriate engraftment.

24 , in addition to sustained hypoxia following engraftment.

25 manipulations required to improve xenoislet engraftment.

26 crobiota raises barriers to donor microbiota engraftment.

27 splant donor irradiation prevented long-term engraftment.

28 of hematopoietic stem cell transduction and engraftment.

29 cessory, non-HSC to accelerate hematopoietic engraftment.

30 l (>95%) vs low-level (5%-49%) donor myeloid engraftment.

31 bone marrow tumor burden upon i.v. leukemic engraftment.

32 they recover from chemotherapy and stem-cell engraftment.

33 ly important for mammary and metastatic lung engraftment.

34 After initially robust engraftment, 3 of these patients experienced declining d

35 ignificant HSC dysfunction including loss of engraftment ability and a myeloid-biased output.

36 expressing HSC showed significantly enhanced engraftment ability.

37 All 25 patients achieved primary neutrophil engraftment after a median of 12 days.

38 These results suggest that engraftment after haploidentical bone marrow transplanta

39 was associated with donor T-cell and myeloid engraftment after HCT.

40 endpoint was detection of early subclinical engraftment after HSCT with (18)F-FLT PET or CT.

41 Host cell competition is a major barrier to engraftment after in utero hematopoietic cell transplant

42 nsights into Thpo-dependent influence on HSC engraftment after transplantation.

43 vivo, CAV1+ Hu-MuSCs demonstrated increased engraftment after transplantation.

44 OPN knockout niche results in a decrease in engraftment, an increase in long-term HSC frequency and

45 transplantation they show superior myofiber engraftment and ability to seed the satellite cell niche

46 serve as adjuvant modalities to enhance HSC engraftment and accelerate hematopoietic recovery in the

47 rogenitor cells (HSPCs) to sustain long-term engraftment and can specifically synergize with the onco

48 can produce therapeutic levels of long-term engraftment and could therefore allow single-step prenat

49 types, including long-term tracking of cell engraftment and differentiation in vivo.

50 t, inflammatory amplifier that enhances TNBC engraftment and dissemination in association with neutro

51 Durable engraftment and donor-specific tolerance can be achieved

52 uced-intensity conditioning, there was rapid engraftment and expansion of a polyclonal pool of transg

53 ion, SA-CD47-engineered islets showed better engraftment and function as compared with the SA-control

54 al treatment, which might allow for improved engraftment and function of the transplanted cells.

55 motherapy and stimulated neuroblastoma tumor engraftment and growth in immunodeficient mice, indicati

56 n human TNBC cells, but rather its effect on engraftment and growth in vivo required neutrophils.

57 gh) TAMs also significantly accelerate tumor engraftment and growth in vivo.

58 ts, we found significantly improved rates of engraftment and GVHD following TLI/ATS/CTX compared with

59 and immunohistochemistry were used to assess engraftment and immune reconstitution.

60 haplocord stem cell transplant assures good engraftment and leads to acceptable toxicity and disease

61 ignificant inflammatory mediators of mammary engraftment and lung metastatic growth in triple-negativ

62 Additionally, BALOs support engraftment and maintenance of the cellular phenotype of

63 islets (NPIs) in vitro and determined islet engraftment and metabolic outcomes when cotransplanted i

64 r tumors, coinjection of MCs increased tumor engraftment and outgrowth, supporting the link between M

65 report that impaired IL-7R signaling hampers engraftment and progression of patient-derived T-ALL xen

66 ld enhance allogeneic bone marrow cell (BMC) engraftment and promote tolerance induction.

67 out myelosuppression, as demonstrated by the engraftment and recovery of multilineage descendants of

68 ble of supporting allogeneic donor stem cell engraftment and regeneration of spermatogenesis.

69 he expanded cells also demonstrated improved engraftment and repopulation in serial transplantation a

70 -beta/Fc had a synergistic effect to promote engraftment and resulted in significantly higher donor c

71 ncing approach enabled precise monitoring of engraftment and revealed clonal evolution of oncogenic c

72 nditioning with CD45-SAP allows multilineage engraftment and robust immune reconstitution in mice wit

73 ents were assessed for primary end points of engraftment and safety and for hematologic and clinical

74 ietic stem cells, and can be used for clonal engraftment and serial primary and secondary multi-linea

75 hematopoietic niche remodels to promote HSPC engraftment and suggests that cxcl8/cxcr1 signaling is a

76 erefore, have the potential to improve islet engraftment and survival.

77 We showed that T(reg) engraftment and therapeutic benefit in nonautoimmune mod

78 result in loss of kidney function and limit engraftment and therapeutic effects of renal epithelial

79 Here, we evaluated T(reg) engraftment and therapeutic efficacy in the nonobese dia

80 phin-1 as a powerful cytokine promoting cell engraftment and thus improving cell therapy of the infar

81 Engraftment and/or expansion of HSPCs was dependent on t

82 All patients had engraftment, and adverse events were consistent with eff

83 percentages of neuronal markers, better hNSC engraftment, and improved behavioral recovery.

84 ilored scaffolding maintained hMSC stemness, engraftment, and led to robust motosensory improvement,

85 e tissue healing by directing hMSC survival, engraftment, and reparative activities.

86 mia, to those undergoing allogeneic HSCT pre-engraftment, and to those receiving systemic immunosuppr

87 aches to modify transplanted organs prior to engraftment as a method to reduce rejection, focusing on

88 e primary objective was modified to evaluate engraftment, assessed by chimerism.

89 The cumulative incidence of neutrophil engraftment at day 42 was 94%.

90 HSC infusion, which was up to 20 days before engraftment became clinically evident.

91 in vitro; however, these constructs present engraftment, biocompatibility, and cell functionality li

92 matopoietic stem and progenitor cells during engraftment but also improves transplantation outcome wi

93 .3 years; P = 0.80) and diabetes duration at engraftment but with significant different mean HbA1c le

94 y enhanced thymopoiesis and periphery T-cell engraftment, but also significantly increased class swit

95 In addition, pFUS was able to enhance the engraftment by facilitating islet revascularization and

96 daptive immune systems, complete with tissue engraftment by human mast cells that are competent to mo

97 tion of host muscle enhances donor stem cell engraftment by promoting the proliferation of transplant

98 vivo culture offers one approach to increase engraftment capacity by seeking to expand stem and proge

99 l for hematopoietic cell maintenance and HSC engraftment capacity in adult hematopoiesis.

100 es aging of old HSCs, resulting in increased engraftment, decreased HSC frequency, increased stem cel

101 thally irradiated mice results in a profound engraftment defect in tertiary and quaternary recipients

102 ssion of SRF or beta2 integrins rescues HSPC engraftment defects associated with mDia2 deficiency.

103 Tumour engraftment did not occur in one of the five immunised T

104 After engraftment, donor DCs assume the same role, maintaining

105 Microbiome end points included SER-287 engraftment (dose species detected in stool after but no

106 therapy (PBMT) to significantly enhance the engraftment efficacy of hUCB HSCs and progenitor cells (

107 ming capacity of GBM cells, as well as tumor engraftment efficiency in both male and female mice.

108 king of stem cells that demonstrate a higher engraftment efficiency than those mobilized by G-CSF.

109 mice receiving a SCI before or after stable engraftment exhibit significantly different neuroinflamm

110 standing the subclinical pathway to cellular engraftment following haemopoietic stem cell transplanta

111 ting in impaired tissue homeostasis, reduced engraftment following transplantation and increased susc

112 le levels of stable, long-term hematopoietic engraftment for up to 24 weeks post-IUHCT.

113 The cumulative incidence of pre-engraftment GNB was 17.3% in allo-HSCT and 9% in auto-HS

114 , but a limited number and a low efficacy of engraftment greatly restrict their clinical use.

115 1 (UCP1)(+pos) adipose tissue with long-term engraftment (>4 mo).

116 ment for tumor-expressed CXCR3 in metastatic engraftment has been demonstrated, the role of monocyte-

117 nables direct histologic comparison of early engraftment immunobiology.

118 VLA4+NPC engraftment in 4L;C* brain also led to enhanced expressi

119 th donor satellite cells promoted donor cell engraftment in a few instances, suggesting that a rare,

120 ha2beta1 integrin, prolong hMSC survival and engraftment in a segmental bone defect and result in imp

121 d CXCR4 inhibitors impair SOX11-enhanced MCL engraftment in bone marrow.

122 CD45-SAP enabled high levels of multilineage engraftment in both Rag1 mutant models, allowed overcomi

123 Neutrophil and platelet engraftment in both the MUD and MMRD groups occurred on

124 differentiated kidney tissue, strategies for engraftment in experimental animals, and development of

125 th cell-free scaffolds, and the rate of cell engraftment in hCMP-treated animals was 24.5% at week 1

126 1 is a novel major regulator of adhesion and engraftment in human HSPCs through mechanisms that, at l

127 VKAs decrease human HSC engraftment in immunosuppressed mice.

128 ifferent injury phenotype to that seen after engraftment in kidney transplants with or without CI.

129 dults with obesity results in gut microbiota engraftment in most recipients for at least 12 weeks.

130 city to promote multi-lineage haematopoietic engraftment in mouse hosts.

131 ion proteins to the conditioning resulted in engraftment in nearly 100% of recipients.

132 means or by neutralizing antibodies prevents engraftment in pancreatic xenograft models.

133 opoietic stem cell (HSC) transplantation and engraftment in recipient mice.

134 J-Lat cells exhibited successful engraftment in several tissues including spleen, bone ba

135 -matched iPSC-derived neurons provide better engraftment in the brain, with a lower immune response a

136 onocytes/macrophages in the process of tumor engraftment in the lung.

137 BM cells between parabionts but significant engraftment in the spleens.

138 only slightly enhanced donor satellite cell engraftment in this mouse strain, suggesting either that

139 s less than 5 minutes, shows efficient tumor engraftment in two-thirds of mice, and can be achieved u

140 tibody production and suppress IL26-enhanced engraftment in vivo, suggesting that targeting this infl

141 tion, as well as tumorigenesis in orthotopic engraftments in mice.

142 ed virus vector increased human CD45(+) cell engraftment, including an increase in human regulatory T

143 Following engraftment into immunodeficient mice, transduced HSPCs

144 Upon engraftment into murine rectal mucosa, human RC tumoroid

145 zation of 3D bioprinted cardiac patches with engraftment into native rat myocardium.

146 okines that improve mesenchymal stromal cell engraftment into the heart both in normal conditions and

147 Larval engraftment is a powerful short-term transplant platform

148 However, a major limitation of PBMC engraftment is development of acute xenogeneic graft- ve

149 Allogeneic BMC engraftment is enhanced with TGF-beta/Fc fusion protein

150 High-level donor myeloid engraftment is important for platelet reconstitution aft

151 Following engraftment, islet function can be monitored in vivo by

152 This engraftment led to interferon-gamma-dependent functional

153 ce resulted in significantly lower long-term engraftment levels, associated with a reduced capacity o

154 Thus, paratope engraftment may be used to expand the epitope repertory

155 The enhanced engraftment may result from a PBMT-mediated increase of

156 antation of ENCDCs into this region leads to engraftment, migration, and differentiation of enteric n

157 human and mouse islet apoptosis and improves engraftment most effectively in the portal and DL subcut

158 s of insulin expression suggested that islet engraftment numbers were close to 1000 IEQ transplanted.

159 recruitment, resulting in multifold greater engraftment of allogeneic hepatocytes and substantially

160 of PEG to ALG in MicroMix capsules improved engraftment of allogeneic islets in the IP site, but res

161 The biomaterial-based vaccine prevented the engraftment of AML cells when administered as a prophyla

162 This novel combinatorial therapy promotes engraftment of autoantigen-specific donor T(regs) and co

163 Ectopic engraftment of BAPC-derived BAT in skeletal muscle augme

164 Finally, flow cytometry confirmed low-level engraftment of BM cells between parabionts but significa

165 achieved by immune regulation without actual engraftment of BMSCs.

166 hepatic VEGF, which enhances recruitment and engraftment of bone marrow sprocs after liver injury.

167 nhibition markedly increased recruitment and engraftment of bone marrow sprocs, whereas systemic MMP

168 ritical for the survival, proliferation, and engraftment of c-KIT(+) EC progenitors in the neonatal l

169 Engraftment of C57BL/6 mice with TIB-49 AML led to an ex

170 round (NSGS mice), we demonstrate remarkable engraftment of CMML and JMML providing the first example

171 Engraftment of CMML and JMML resulted in overt phenotypi

172 ononuclear cells (n = 10) resulted in robust engraftment of CMML in BM, spleen, liver, and lung of re

173 Through the orthotopic engraftment of colon organoids we describe a broadly usa

174 The progressive engraftment of corrected HSCs in non-conditioned patient

175 We observed variable engraftment of donor bacterial groups among FMT recipien

176 s, although this was primarily driven by the engraftment of donor species, which remained at low abun

177 Engraftment of dose species was facilitated by vancomyci

178 Temporal engraftment of electrical excitable nodal-like cardiomyo

179 PD-L1 signaling is not required for engraftment of embryonic HSCs.

180 Engraftment of engineered mesenchymal stromal cells (eMS

181 Mechanistically, IL6 diminished engraftment of FoxP3(+) donor T cells, corresponding wit

182 We found improved engraftment of fully allogeneic BALB/c islets in Micro c

183 e therapy studies have failed to demonstrate engraftment of gene-corrected hematopoietic stem and pro

184 nt reduction in sickling of red blood cells, engraftment of gene-edited SCD HSPCs in vivo and the imp

185 Engraftment of genetically corrected HSPCs was successfu

186 y endpoints were overall survival, sustained engraftment of genetically corrected HSPCs, expression o

187 Engraftment of hiPSC-derived adipocytes in mice produces

188 stigation demonstrates that PBMT can promote engraftment of hUCB HPSCs, at least in part, via ROS-med

189 an PBMCs into both strains enabled long-term engraftment of human CD4(+) and CD8(+) T cells without a

190 e model can be further humanized through the engraftment of human hematopoietic stem cells (HSCs) tha

191 , but retention of T-cell function following engraftment of human peripheral blood mononuclear cells

192 Successful co-engraftment of human skin, autologous lymphoid tissues,

193 Some of the recognized challenges are poor engraftment of implanted cells and, in the case of human

194 emic MMP inhibition enhanced recruitment and engraftment of infused allogeneic progenitors.

195 ostasis, induced aplasia, early settling and engraftment of infused cells, and later recovery of lymp

196 cell therapy are still unclear, and limited engraftment of iPSC-derived cardiomyocytes is well known

197 th dexamethasone and dasatinib also impaired engraftment of leukemia cells in vivo.

198 anous-related formin mDia2 leads to impaired engraftment of long-term hematopoietic stem cells and lo

199 on of CD4(+) T cells greatly facilitated the engraftment of lymphoma cells in serial transplantation

200 Engraftment of mast cell-deficient mice with Tph1(-/-) m

201 mediator release upon degranulation, and 4) engraftment of MC-deficient Kit (W-sh/W-sh) mice with ad

202 Engraftment of MCs restored both bacterial clearance and

203 In particular, pulmonary vascular engraftment of miR-210-positive interstitial lung macrop

204 ssue regeneration, and markedly enhanced the engraftment of muscle stem cells in injured and noninjur

205 mmunodeficient mice resulted in reproducible engraftment of myeloid, lymphoid, and CD34(+) cells.

206 nged depending on the context to improve the engraftment of nonengrafting acute myeloid leukemia (AML

207 mmunodeficient mouse strains with high-level engraftment of normal and diseased human immune/hematopo

208 proliferation, and self-renewal signals for engraftment of normal and malignant blood cells.

209 Anti-CD117 mAbs also facilitate the engraftment of normal donor human HSCs in MDS xenograft

210 ecessary prerequisite is satisfied for using engraftment of olfactory stem and progenitor cells as a

211 can non-invasively enhance the function and engraftment of pancreatic islets following transplantati

212 4, Il5, and Csf2 in the retina, and abnormal engraftment of peripheral CCR2(+) CX3CR1(+) monocytes in

213 , and find that in AML, TRC105 prevented the engraftment of primary AML blasts and inhibited leukemia

214 herefore, allow for accelerated and superior engraftment of primary patient-derived acute myeloid leu

215 Engraftment of SA CMCs was negligible, which implies a p

216 Engraftment of SER-287 and changes in microbiome composi

217 Engraftment of some Actinobacteria, and engraftment or l

218 2 suppressed the in vitro growth and in vivo engraftment of T-ALL cells via diminished LMO2 deacetyla

219 Bone marrow engraftment of the hematopoietic stem and progenitor cel

220 Orthotopic engraftment of the neural progenitor cells derived from

221 The co-engraftment of these human skin and immune system compon

222 Re-engraftment of these primary tumor neurospheres generate

223 e toxic effects and resulted in multilineage engraftment of transduced cells, reconstitution of funct

224 elial growth factor (VEGF) enhances vascular engraftment of transplanted cells but the efficacy is lo

225 The engraftment of transplants was tracked over time, illust

226 oietic recovery with polyclonal multilineage engraftment of vector-marked cells was achieved, with a

227 of vancomycin preconditioning on expansion (engraftment) of SER-287 species in the colon.

228 and continued until 7 days after neutrophil engraftment or completion of fluoroquinolone prophylaxis

229 Engraftment of some Actinobacteria, and engraftment or loss of Proteobacteria, were related to b

230 ect hematopoietic stem cell differentiation, engraftment, or mobilization, which are known to depend

231 ct risk for chronic GVHD, hematopoietic cell engraftment, overall mortality, or nonrelapse mortality.

232 Multivariable analysis revealed neutrophil engraftment (p < 0.001; p = 0.021) and female sex (p = 0

233 up and in the lymphoma group, and neutrophil engraftment (p = 0.008) in the MM group.

234 tion and reduced vascular fenestration after engraftment, partially impairing vascular permeability a

235 zeta CAR T cells, which likely underlies the engraftment persistence observed with this CAR design.

236 rming capacity, and showed similar long-term engraftment potential in vivo as untreated cells.

237 knockdown of MTCH2 decreased growth, reduced engraftment potential of stem cells, and induced differe

238 ncement of MMP in old HSCs in vivo increases engraftment potential upon transplantation and reverses

239 (Hi) HSC fraction demonstrates no observable engraftment potential, but directly matures into megakar

240 ineage differentiation potential and in vivo engraftment potential.

241 on, these cells lacked hematopoietic in vivo engraftment potential.

242 Post-engraftment pregnancies should be planned and the terato

243 The engraftment procedure takes less than 5 minutes, shows e

244 imab injection was added to the standard PDX engraftment protocol.

245 proliferation, differentiation and survival/engraftment rate.

246 High engraftment rates are critical to any patient-derived xe

247 Poor survival and vascular engraftment rates of transplanted cells force them to wo

248 EC differentiation, capillary engraftment, reduced capillary permeability, and re-esta

249 in irradiated host muscle promote donor cell engraftment remains elusive.

250 tive molecule identified by this competitive engraftment screening was cardiotrophin-1, a member of t

251 ng, estimation of HUVEC retention within the engraftment site 4 hr post-administration was 24.5 +/- 3

252 Here, we developed an engraftment strategy to examine age-associated human isl

253 h to 37 degrees C, and 28 d are required for engraftment studies.

254 inhibition of complement receptors prevents engraftment syndrome and allows their homing to secondar

255 t, MSCs home to the graft where they promote engraftment syndrome and do not induce Treg.

256 Upon engraftment, the transcriptome of reisolated Pax3/Pax7-i

257 ive therapy to facilitate islet function and engraftment, thereby improving the outcome of diabetic p

258 glandin E2 (PGE2) stimulates HSC renewal and engraftment through, for example, induction of the cAMP

259 ssue formation in vivo and undesirably short engraftment time.

260 Transplacental maternal engraftment (TME), the presence of maternal T cells in p

261 operties of MLL-AF9 cells and promoted their engraftment to bone marrow.

262 a combination of cell ablation and precursor engraftment to investigate the generation of gut macroph

263 Tumor engraftment to lung was impaired in CXCR3(-/-) mice, and

264 al GvHD, and stable, disease-free full donor engraftment using reduced intensity conditioning and mob

265 The median time to platelet engraftment was 27 days.

266 Engraftment was assessed by flow cytometry.

267 In vivo islet engraftment was assessed by transplantation into diabeti

268 Colonization with these groups at engraftment was associated with a 60% lower risk of CDI,

269 Engraftment was associated with low levels of intrahepat

270 Results Engraftment was comparable between both groups.

271 a murine model of metastatic-like melanoma, engraftment was coordinate with CXCR3(+) monocyte/macrop

272 Engraftment was durable in the majority of chimeras and

273 Human cell engraftment was immunohistochemically analyzed on postna

274 Successful engraftment was recorded after a median of 11 d (range,

275 Stable full donor engraftment was significantly greater at 80% among TCRal

276 vivo, the ability of MSCs to facilitate HSC engraftment was tested in a xenogenic transplant model,

277 of CS-CMVi, and the time from transplant to engraftment was the only predictor of mortality.

278 Despite engraftment, we did not observe clinically significant m

279 Our aim was to improve multilineage engraftment; we tested nongenotoxic conditioning with an

280 depleted from mPBMC, long-term survival and engraftment were achieved in majority of the recipients.

281 Host stromal ME recovery and donor HSPC engraftment were augmented after mitochondria transfer.

282 Median times to neutrophil and platelet engraftment were comparable.

283 splant conditioning period through stem cell engraftment were used in the analysis.

284 fficacy in preventing IBMIR to promote islet engraftment when compared to "state-of-the art" treatmen

285 s-mediated chemotaxis, homing, and long-term engraftment when these cells were transplanted into prim

286 romising approach to deriving functional BAT engraftment, which may be applied to therapeutic BAT tra

287 iation from 200 cGy to 400 cGy would improve engraftment while maintaining the safety profile.

288 Mice were treated 13 days post-engraftment with an intravenous injection of (212)Pb-Dar

289 Mice were treated 13 d after engraftment with an intravenous injection of (212)Pb-dar

290 demonstrated high levels of peripheral blood engraftment with E6 T-cell receptor T cells 1 month afte

291 ed T cells into patients resulted in durable engraftment with edits at all three genomic loci.

292 em cell factor (huNSG) mice exhibited robust engraftment with functional human T and B lymphocytes an

293 was dependent on IL-6 released from MCs, and engraftment with IL-6-deficient MCs failed to control wo

294 ckpoint to mitigate IBMIR for enhanced islet engraftment with translational potential.

295 Donor cell engraftment within non-irradiated dystrophic host mouse

296 ter alphaCD3 alone resulted in robust T(reg) engraftment within the islets and induced remission in a

297 splant recipients are limited by poor T(reg) engraftment without host manipulation.

298 tity, and allowed highly efficient donor-HSC engraftment without irradiation.

299 ion, innate immune surveillance impacts cell engraftment, yet a strategy to control both, adaptive an

300 sulted in a 43-fold increase in donor T(reg) engraftment, yet polyclonal donor T(regs) failed to reve